Belief BioMed Group announced the completion of patient dosing in its Phase III Registrational Clinical Trial of BBM-H901, a gene therapy for Hemophilia B developed and manufactured in-house by Shanghai Belief-Delivery Biomed Co., Ltd., its wholly owned subsidiary.
